Handelsavisen
prelaunch
Companies ›Healthcare ›DVLA.JK
DV
DVLA.JK — IDX (Jakarta) Pharmaceuticals

Dvla.Jk

$1 600,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
6,73 %
Op margin
9,7 %
ROE
11,1 %
Net margin
7,3 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

DVLA.JK is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

Business. DVLA.JK is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
11,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning DVLA.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to DVLA.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    DVLA.JK is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    DVLA.JK maintains a strong liquidity position, with a current ratio of 2.45, indicating that the company has more than twice the current assets to cover its current liabilities. The company's free cash flow of 9.01 billion is positive, but relatively low compared to its operating cash flow of 201.14 billion, suggesting that capital expenditures are consuming a significant portion of operating cash.

    In terms of profitability, DVLA.JK reports a return on equity (ROE) of 11.08% and a return on assets (ROA) of 6.98%, both of which are strong indicators of efficient use of equity and assets. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators.

    The company's revenue is concentrated within the pharmaceuticals segment, with no disclosed geographic breakdown. This suggests that DVLA.JK's operations are primarily focused on a single business line, which may increase its exposure to sector-specific risks.

    Looking ahead, DVLA.JK is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditures are expected to remain a drag on free cash flow, as they were in the current fiscal year.

    DVLA.JK faces a medium liquidity risk, as indicated by its current ratio and free cash flow. The company's debt-to-equity ratio is 0.0, suggesting that it is not currently leveraging debt to finance operations. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints in the future.

    Recent filings and transcripts do not indicate any major events that would significantly impact DVLA.JK's operations or financial position. The company appears to be operating within a stable regulatory and market environment.

    Key takeaways
    • DVLA.JK has a strong liquidity position with a current ratio of 2.45.
    • The company's ROE of 11.08% and ROA of 6.98% indicate efficient use of equity and assets.
    • Revenue is concentrated in the pharmaceuticals segment, with no geographic diversification disclosed.
    • Capital expenditures are consuming a significant portion of operating cash flow.
    • The company's liquidity risk is medium, with a negative net cash position after debt.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 600,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.48T
    Net cashⓘ
    -$206.9M
    Current ratioⓘ
    2.5
    Debt / equityⓘ
    0.0
    ROAⓘ
    7.0%
    ROEⓘ
    11.1%
    Cash conversionⓘ
    123.0%
    CapEx / revenueⓘ
    -4.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin9,7 %Above median
    Net Margin7,3 %Above median
    ROE11,1 %Above P75
    Capex / Rev-4,8 %Above median
    D/E0,00Above P75
    Cash Conv1,23Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • DVLA.JK Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    DVLA.JKCanonical
    IDX (Jakarta) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage